Periodontal Therapeutics Market Size & Share 2024 – 2032

Periodontal Therapeutics Market Size

Periodontal Therapeutics Market size was valued at around USD 849.2 million in 2023 and is estimated to grow at 7.7% CAGR from 2024 to 2032. Periodontal therapeutics refers to the medical and dental treatments used to manage and treat periodontal diseases, which are infections and inflammations of the structures around the teeth, including the gums, periodontal ligament, and alveolar bone. The goal of periodontal therapeutics is to halt the progression of periodontal disease, promote healing, and maintain the health of the periodontium.

The increasing prevalence of periodontal diseases, such as gingivitis and periodontitis, are linked to rising rates of diabetes, cardiovascular diseases, and aging populations globally. Innovations in treatment modalities, including advanced local delivery systems for antibiotics like minocycline hydrochloride and doxycycline hyclate, are enhancing the efficacy and patient compliance of periodontal therapies.
 

Additionally, growing awareness and emphasis on oral hygiene and dental preventative supplies contribute to the rising demand for periodontal treatments. The integration of new technologies, such as antimicrobial photodynamic therapy and laser therapy devices, further propels market growth by offering less invasive and more effective options. Moreover, increasing investment in research and development by pharmaceutical companies to develop novel therapeutics and improve existing treatments is expected to sustain market expansion.
 

Periodontal Therapeutics Market Trends

• The shift towards localized antibiotic therapies, such as minocycline hydrochloride and doxycycline hyclate, which offer targeted treatment with reduced systemic side effects, is a significant trend expected to boost the market growth.
   
• Another notable trend is the increasing use of non-antibiotic antimicrobials like chlorhexidine gluconate, known for its effectiveness in plaque control and gingival inflammation reduction.
   

Periodontal Therapeutics Market Analysis

Based on product, the market is bifurcated into local antibiotic therapy and systemic antibiotic therapy. The systemic antibiotic therapy segment dominated the market with the largest revenue of USD 530.3 million in 2023.
 

• The efficacy of systemic antibiotics in controlling infections that cannot be adequately managed with local treatments alone is expected to boost the segment growth over the forecast period.
   
• Additionally, antibiotics such as doxycycline hyclate and metronidazole benzoate are particularly effective against the complex bacterial flora associated with aggressive and necrotizing periodontal diseases.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on type, the periodontal therapeutics market is segmented into chronic periodontal disease, gingivitis, aggressive periodontal disease, necrotizing periodontal disease, and other types. The chronic periodontal disease segment dominated the market and was valued at USD 369.1 million in 2023.
 

• Advances in therapeutic approaches, such as host modulation therapy, focus on altering the body's response to the bacterial challenge rather than merely targeting the bacteria. Advances in therapeutic approaches, such as host modulation therapy, focus on altering the body's response to the bacterial challenge rather than merely targeting the bacteria.
   
• Additionally, regenerative techniques using growth factors and tissue engineering are being explored to restore lost periodontal structures. By addressing both the microbial and host response elements of chronic periodontal disease, these therapeutic strategies aim to preserve oral health and prevent tooth loss.
   

Based on distribution channel, the periodontal therapeutics market is segmented into retail pharmacies, e-commerce, drug stores, and hospital pharmacies. The retail pharmacies segment held the largest revenue of USD 351.1 million in 2023.
 

• There is an increasing prevalence of periodontal diseases such as gingivitis and periodontitis, driven by aging populations, poor oral hygiene, and lifestyle factors like smoking and poor diet, resulting in a growing demand for periodontal therapeutics.
   
• Additionally, the convenience and accessibility of retail pharmacies make them a preferred choice for patients seeking immediate and easy access to these therapeutics.
   

The North America periodontal therapeutics market is forecasted to reach USD 756.7 million by 2032, propelled by rapidly aging population, technological advancements, heightened public awareness, and the rising prevalence of chronic diseases. The U.S. dominated the North America market with the largest revenue of USD 354.7 million in 2023.
 

• The market in North America is primarily driven by an increasing prevalence of periodontal diseases, growing awareness about oral health, and advancements in dental treatment technologies.
   
• Additionally, a rise in the adoption of minimally invasive procedures and the availability of innovative products such as locally administered antibiotics, systemic antibiotics, and laser therapy bolster the demand for periodontal therapeutics.
   

The periodontal therapeutics market in UK is expected to experience significant and promising growth from 2024 to 2032.
 

• Public awareness campaigns and NHS initiatives in the UK, underscore the importance of oral health, emphasizing early diagnosis and prevention.
   
• Additionally, economic factors, including the allocation of healthcare funding and the cost-effectiveness of various treatments, influence the accessibility and prioritization of periodontal care.
   

Japan periodontal therapeutics market is anticipated to witness lucrative growth between 2024 – 2032.
 

• The high proportion of elderly individuals requires effective treatments to manage chronic conditions like periodontitis, which can significantly impact overall health and quality of life.
   
• Moreover, Japan's robust pharmaceutical and biotechnology sectors are actively involved in researching and developing new therapeutic agents and treatment modalities, supported by government policies and funding aimed at advancing medical research.
   

The periodontal therapeutics market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.
 

• The government's initiatives, such as the Saudi Vision 2030, aim to improve healthcare infrastructure and accessibility, thereby boosting the dental care sector.
   
• Additionally, the prevalence of periodontal diseases, exacerbated by high rates of diabetes and smoking in the population, necessitates effective therapeutic interventions. Cultural practices, such as the use of the miswak (a traditional teeth-cleaning stick), also play a role in oral hygiene habits and treatment approaches.
   

Periodontal Therapeutics Market Share

The periodontal therapeutics sector is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A pivotal aspect of market strategy involves the continual introduction of innovations such as the application of regenerative medicine, including the use of growth factors and stem cell therapy.
 

Notably, prominent industry players command considerable influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding global footprint amidst evolving regulatory landscapes.
 

Periodontal Therapeutics Market Companies

Some of the eminent market participants operating in the periodontal therapeutics industry include:

• Align Technology, Inc.
• Bausch Health Companies Inc.
• Cadila Healthcare Ltd.
• Colgate-Palmolive Company
• Danaher Corporation
• Den-Mat Holdings LLC
• Dentsply Sirona
• Dexcel Pharma Technologies Ltd.
• GlaxoSmithKline plc
• Henry Schein, Inc.
• Hoffmann-La Roche Ltd.
• Johnson & Johnson Services, Inc.
• Kaken Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Procter & Gamble Co.
• Straumann Holding AG
• Sunstar Suisse SA
• Teva Pharmaceutical Industries Ltd.
• Zimmer Biomet Holdings, Inc.
• 3M Company
   

Periodontal Therapeutics Industry News:

• In January 2024, Pfizer Inc. announced a partnership with Glenmark Pharmaceuticals Ltd., to launch Abrocitinib in India. The drug, developed by Pfizer Inc., will be co-marketed in India under the JABRYUS and CIBINQO brand names. This launch is expected to significant boost the presence of Pfizer Inc. in India.
   
• In May 2023, Bausch Health Companies Inc. (NYSE/TSX: BHC) and its oral health care subsidiary, OraPharma, announced a collaboration with World Series Champion Alex Rodriguez to launch a national awareness campaign on the prevalence and impact of gum disease. The Cover Your Bases campaign featured educational content and encouraged patients to discuss comprehensive treatment options with their dentists. The initiative aimed to enhance public understanding and promote proactive oral health care.
   

The periodontal therapeutics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Local antibiotic therapy
  • Minocycline hydrochloride
  • Doxycycline hyclate
  • Chlorhexidine gluconate
  • Metronidazole benzoate
  • Tetracycline hydrochloride
• Systemic antibiotic therapy
  • Minocycline hydrochloride
  • Doxycycline hyclate
  • Metronidazole benzoate

Market, By Type

• Gingivitis
• Chronic periodontal disease
• Aggressive periodontal disease
• Necrotizing periodontal disease
• Other types

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Drug stores
• E-commerce

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europ 
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific 
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America 
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa